/ /

LATEST

Retirement is around the corner for David Karcher, ASCRS executive director
Retirement is around the corner for David Karcher, ASCRS executive directorDavid Karcher, executive director and chief executive officer, The American Society of Cataract and Refractive Surgery (ASCRS), will retire as of December 31, 2018, according to an ASCRS press release. Eric D. Donnenfeld, MD, will chair the search committee responsible for interviewing candidates to fill the role of executive director. Interviews will begin in the late summer or early fall of 2017. Leonard Pfeiffer & Company, a well-known executive search firm, will be assisting in the search.
Pros and cons of compounded pharmaceuticalsCompounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Endoillumination growth amplifies tissue visualizationEndoillumination for vitreoretinal surgery continues to improve with the introduction of brighter, safer light sources with color filters that may allow opportunities for better tissue visualization.
Community mourns loss of ophthalmic leader, Roger Steinert, MD
Community mourns loss of ophthalmic leader, Roger Steinert, MDThe ophthalmic community mourns the loss of Roger Steinert, MD, an internationally renowned and respected corneal, cataract, and refractive surgeon. Dr. Steinert passed away on June 6 at the age of 66 after a 2 ½-year battle with glioblastoma. He died peacefully at his home in Colorado, surrounded by his wife, April, and their family.
NICE recommends dexamethasone adalimumab for uveitisThe UK’s National Institute for Health and Care Excellence (NICE) has given preliminary approval to dexamethasone 0.7 mg intravitreal implant (Ozurdex, Allergan) and adalimumab (Humira, AbbVie) for sight-threatening non-infectious posterior uveitis.
Access, costs of bevacizumab key factors for DME therapyThe efficacy of intravitreal bevacizumab (Avastin, Genentech) for improving vision in patients with center-involving diabetic macular edema (DME) has been demonstrated in several clinical trials.
Data clearly demonstrates bevacizumab’s inferiority for DMEAll three anti-vascular endothelial growth factor (anti-VEGF) agents that are commercially available have demonstrated efficacy for the treatment of diabetic macular edema (DME). However, it is clear from the results of clinical trials that outcomes with bevacizumab are not as good as those obtained using ranibizumab or aflibercept, according to Jean-François Korobelnik, MD.
Vitrectomy beats scleral buckling in rhegmatogenous retinal detachment studyEyes operated on with pars plana vitrectomy needed fewer reoperations over 180 days than eyes subjected to scleral buckling (SB) in a retrospective comparison of patients with rhegmatogenous retinal detachment (RRD).
Limiting inflammation may decrease nerve damage, preserve cell functionEvidence supports the involvement of an important pathway in retinal ganglion cell dysfunction and death in traumatic optic neuropathy.

Poll

View Results